Answers before the first call.

We work on cross-border life-science transactions – in-licensing and out-licensing, strategic partnerships, M&A, and NewCo formation. Each engagement is partner-led from the first call through close, with a senior team that stays on the file rather than handing it down.

Both. We represent originators seeking the right home for a differentiated asset, and we run disciplined sourcing for acquirers and partners building a pipeline. We do not take dual mandates on the same asset, and we disclose our side at the outset.

Our network runs deepest across Oncology, Immunology, Metabolic, Cell & Gene, CNS, Rare Disease, Devices & Diagnostics, and Digital Health. We are modality-agnostic, from small molecules through cell and gene therapy.

Bespoke to the mandate. We typically combine a retainer that funds senior diligence and outreach with a success component aligned to a closed transaction. Structure is set before any work begins, written into a single engagement letter – no fee table, no surprises.

Most mandates run four to nine months from term sheet to close, depending on diligence depth, counterparty count, and regulatory complexity. We scope a realistic timeline in the first conversation and update it as the deal develops.

We focus on transactions where committed economics generally range from $25M to $1B+. That said, the strength of the asset and the fit of the corridor matter more than a headline number – we are happy to assess earlier-stage situations on their merits.

We are NDA-first. No diligence material, counterparty identity, or deal detail moves before a mutual non-disclosure agreement is in place. Access is limited to the named partners on your file, and information is shared on a strict need-to-know basis throughout.

Every new mandate is run through a conflict check against active and recent engagements before we accept. If a conflict exists, we tell you and decline rather than wall it off. We will not work both sides of the same asset.

Cairo is our headquarters, with desks in Dubai, London, and Boston. One integrated team works across all four markets, so a mandate is covered through Africa, the Gulf, Europe, and the United States without handoffs between offices.

Yes. Our four offices anchor the corridors we know best, but our network extends across global pharma and biotech. Where a counterparty sits beyond our desks, we bring the right local relationships into the process.

We do. Cross-border activity with China is a distinct workstream for us, from asset sourcing and diligence to structuring deals that hold up across jurisdictions. Our China Biotech practice covers the corridor end to end.

Send a short note through our contact page describing the asset or mandate at a high level – no confidential detail needed yet. A partner responds within 24 hours, and if there is a fit we put an NDA in place before going deeper.

A clear sense of your objective and the stage of the asset is enough. The strategic question, the geography in play, and your timeline help us be useful quickly. We handle the structure, the outreach, and the process from there.